lapatinib has been researched along with Minimal Disease, Residual in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alladin, A; Burwinkel, B; Garcia, M; Gibson, TJ; Havas, KM; Jechlinger, M; Kafkia, E; Klaus, B; Milchevskaya, V; Patil, KR; Pruneri, G; Radic, K; Rotmensz, N; Schneeweiss, A; Sotillo, R; Stolte, J | 1 |
| Bastida, CC; Falchook, GS; Kurzrock, R; Lippman, SM | 1 |
| Anders, CK; Barry, WT; Berry, DA; Carey, LA; Cheang, MC; Cirrincione, CT; Harris, LN; Henry, NL; Hoadley, KA; Hudis, CA; Iglesia, M; Krop, IE; Ollila, DW; Perou, CM; Pitcher, BN; Singh, B; Weckstein, DJ; Winer, EP | 1 |
1 trial(s) available for lapatinib and Minimal Disease, Residual
| Article | Year |
|---|---|
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogen Receptor alpha; Female; Gene Expression; Humans; Immunoglobulin G; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Trastuzumab; Treatment Outcome; Tumor Microenvironment; Tumor Suppressor Protein p53; Young Adult | 2016 |
2 other study(ies) available for lapatinib and Minimal Disease, Residual
| Article | Year |
|---|---|
Metabolic shifts in residual breast cancer drive tumor recurrence.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lipid Metabolism; Metabolic Networks and Pathways; Mice; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxidative Stress; Progesterone; Quinazolines; Reactive Oxygen Species; Transcriptome; Xenograft Model Antitumor Assays | 2017 |
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm, Residual; Quinazolines; Receptor, ErbB-2; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab; Vascular Endothelial Growth Factor A | 2014 |